By Evan Riley, M.Res, MBA, LSSBB, Senior Process Engineer, Kymanox Corporation
Gene therapy has gained popularity in recent years and is providing new therapeutic products for diseases with few or no treatment options. Researchers can correct diseases by inserting a correct version of a particular gene into a patient’s genome. However, manufacturing these products is a complicated and inefficient process compared to conventional biomanufactured active pharmaceutical ingredients. The complications in manufacturing lead to high drug prices and thus limited patient use.